EWTX - Edgewise Therapeutics

-

$undefined

N/A

(N/A)

Edgewise Therapeutics NasdaqGS:EWTX Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Location: 1715 38th Street, Boulder, CO, 80301, United States | Website: https://edgewisetx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.101B

Cash

436.4M

Avg Qtr Burn

-29.57M

Short % of Float

20.26%

Insider Ownership

0.53%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Sevasemten (EDG-5506) Details
Becker Muscular Dystrophy

Phase 2

Data readout

Sevasemten (EDG-5506) Details
Becker Muscular Dystrophy

Phase 2

Data readout

EDG-7500 Details
Hypertrophic cardiomyopathies (HCM)

Phase 2

Data readout

Sevasemten (EDG-5506) Details
Duchenne muscular dystrophy, Rare diseases

Big Mover™

Susp. Mover™

Phase 2

Data readout

Sevasemten (EDG-5506) Details
Rare diseases, Duchenne muscular dystrophy

Big Mover™

Susp. Mover™

Phase 2

Data readout

Sevasemten (EDG-5506) Details
Rare diseases, Limb-Girdle Muscular Dystrophy, McArdle disease

Phase 2

Update

Sevasemten (EDG-5506) Details
Becker Muscular Dystrophy

Phase 1b

Update